OSAT - Vertex Pharmaceuticals Orange CureVac among premarket losers' pack

Orphazyme (ORPH) -49% Orphazyme stock losing half its value premarket, after rocketing fourfold the day beforeCVR Energy (CVI) -18%.Curis (CRIS) -13% on updated data for CA-4948 in blood cancers.Galecto (GLTO) -16%.Aptose Biosciences (APTO) -15% presents highlights from EHA during corporate update event on the current clinical status of luxeptinibVertex Pharmaceuticals (VRTX) -14% after Vertex, CRISPR Therapeutics present new CTX001 data in beta thalassemia and sickle cell disease.Antelope Enterprise Holdings (AEHL) -13% amid pricing of $3.2M registered direct offering.Sphere 3D (ANY) -13%.Medley Management (MDLY) -12%.Axcella Health (AXLA) -12%.Heat Biologics (HTBX) -10%.SeaChange International (SEAC) -9% on Q1 earnings releaseCureVac (CVAC) -9%.Trxade Group (MEDS) -8%.Orbsat Corp (OSAT) -7%.Birks Group (BGI) -7%.Orange (ORAN) -6%.

For further details see:

Vertex Pharmaceuticals, Orange, CureVac among premarket losers' pack